CMC and Clinical Strategies for the Successful Development of Injectable and Oral Peptide Drugs
Cambridge, MA, United States | 18 September 2024Join us for an enlightening session titled CMC and Clinical Strategies for the Successful Development of Injectable and Oral Peptide Drugs, presented by Dr. Andy Lewis, Chief Scientific Officer. This event will explore critical drivers and innovative delivery options for peptide drugs.
- Understand the drivers and delivery options for peptide drugs
- Discover clinical development strategies to switch delivery routes from IV to subcutaneous
- Learn how it’s possible to phase CMC investment to reduce risk and meet the Target Product Profile
- Hear key CMC and clinical learnings from over 14 oral peptide programs evaluating 10 different permeation enhancers
- Gain insights from the use of PBPK modelling to inform oral peptide development
- Understand the role of rapid clinical pharmacokinetic prototyping to optimize peptide product development
Don't miss this opportunity to enhance your understanding of cutting-edge peptide development and its impact on patient care.
Complimentary validated parking in the Technology Square Garage
| Date/Agenda | Location |
|---|---|
Wednesday, September 18th, 2024Registration: 12:00pm | Catalyst Restaurant 300 Technology Square Cambridge, MA 0213 |
*This is an in person event that will not be recorded. A virtual option to attend is not available.
**We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.